Henlius Builds On Abbott Biosimilar Partnership Gaining 69 Emerging Markets
Launches Of The First Molecules Are Expected In 2027
Henlius casts a wider net for its biosimilars presence by locking in a fresh deal with the already-established partner Abbott. Also, the Chinese biosimilars developer has joined the Biosimilars Forum, securing its footing in the US.
